1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62631A11D5E51D0210025870C006F02E8
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-leveraging-outcomes-data-training-kpi-staffing-economics-outcomes-research-oncology-products?opendocument
18
19opendocument
203.239.58.199
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Health Outcomes

Leveraging Outcomes Data – Training, KPIs, and Staffing in Health Economics & Outcomes Research in Oncology Products

ID: 5688


Features:

7 Info Graphics

10 Data Graphics

80+ Metrics

1 Narratives


Pages/Slides: 25


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Leveraging Outcomes Data: Training, KPIs, and Staffing in Health Economics & Outcomes Research in Oncology Products"

STUDY OVERVIEW

Demonstrating an oncology drug’s value proposition and its potential in real-world practice will maximize business and clinical success. The Health Economics Outcomes Research function is a key player in generating value-oriented outcomes data, but success revolves around constant learning, setting performance indicators and maintaining effective staffing ratios.

This study illustrates the strategies for effective health outcomes data training, KPIs and staffing for oncology products.

Segmentation based on two areas: Geographic responsibility and HEOR reporting structure

KEY TOPICS

  • Executive Summary: Methodology, Participants, & Key Findings
  • Training and KPIs measurement
  • HEOR Staffing and Leadership
  • Lessons Learned
KEY METRICS

I. Training and KPIs Measurement

  • Effective training & development programs for HEOR groups
  • Frequency of training provided to Health Outcomes groups
  • Most effective KPIs and metrics to measure the success of real world data program
  • KPIs measured for successful HEOR program – Market Access vs. Medical Affairs; Global vs. U.S.

II. HEOR Staffing and Leadership
  • Number of field staff that work in the HEOR organization and number of field-based staff dedicated to HEOR structure
  • Number of field staff that work in the HEOR organization and number of field-based staff dedicated to HEOR structure – Global vs. U.S.; Market Access vs. Medical Affairs
  • Leadership level of the HEOR group - Global vs. U.S.; Market Access vs. Medical Affairs

III. Lessons Learned, Success Factors and Pitfalls
  • Top advantages to pursuing HEOR planning earlier in the R&D cycle
  • Top success factors for HEOR in developing and maintaining strong capabilities for work with payer groups
  • Top most difficult challenges or pitfalls for HEOR in developing and maintaining strong capabilities for work with payer groups
SAMPLE KEY FINDINGS
  • KPIs: Measure success of RWD programs through key performance indicators and cover complete development and lifecycle of product
METHODOLOGY

Conducted an operational HEOR benchmark analysis engaging 27 HEOR leaders working across 19 top life-science companies. Report segments included geographic responsibility and functional reporting structure.


Industries Profiled:
Pharmaceutical; Consumer Products; Biotech; Health Care; Laboratories; Diagnostic; Communications; Biopharmaceutical


Companies Profiled:
AbbVie; Merck Serono; Novartis; Astellas; Boehringer Ingelheim; Pfizer; Eisai; Takeda Pharmaceuticals; Ipsen; Merck Sharp & Dohme; Daiichi Sankyo; Alkem; Foundation Medicine; Sun Pharmaceutical; Karyopharm Therapeutics; Brii Biosciences; Nucleus Global; Seattle Genetics

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.